Board Member, Que Oncology
| Role | Organisation | Sources |
|---|---|---|
| Johnson & Johnson | Brandon BioCatalyst portfolio, Brandon Capital portfolio | |
| Board Member | Que Oncology | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Board Member | Kalaris Therapeutics | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Board Member (former) | SteadyMed Therapeutics, Inc. | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| Board Member (former) | Ocean Ridge Charities Association Inc | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
| CCO (former) | POZEN | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Stories naming Elizabeth Cermak. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Biotech company QUE Oncology adds two experienced pharmaceutical executives, Julie Cherrington and Elizabeth Cermak, to its board as it develops a non-hormonal breast cancer therapy.
Clinical-stage biotech QUE Oncology adds two experienced life science executives, Julie Cherrington and Elizabeth Cermak, to its board, while continuing trials of its non-hormonal therapy for breast cancer hot flashes.